Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Ioana Agache, Yang Song, Margarita Posso, et al.
Allergy (2020) Vol. 76, Iss. 1, pp. 45-58
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 1904-1926
Open Access | Times Cited: 154
Advances and highlights in biomarkers of allergic diseases
İsmail Öğülür, Yağız Pat, Özge Ardıçlı, et al.
Allergy (2021) Vol. 76, Iss. 12, pp. 3659-3686
Open Access | Times Cited: 150
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
Thanaporn Ratchataswan, Tina Banzon, Jacob P. Thyssen, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 3, pp. 1053-1065
Open Access | Times Cited: 105
Neuroimmune communication regulating pruritus in atopic dermatitis
Martin Steinhoff, Fareed Ahmad, Atul Kumar Pandey, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1875-1898
Open Access | Times Cited: 85
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 45
Dysregulation of the epithelial barrier by environmental and other exogenous factors
Yasutaka Mitamura, İsmail Öğülür, Yağız Pat, et al.
Contact Dermatitis (2021) Vol. 85, Iss. 6, pp. 615-626
Open Access | Times Cited: 56
From Emollients to Biologicals: Targeting Atopic Dermatitis
Lorenzo Salvati, Lorenzo Cosmi, Francesco Annunziato
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10381-10381
Open Access | Times Cited: 56
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis
Ayobami Akenroye, Grace Lassiter, John W. Jackson, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 150, Iss. 5, pp. 1097-1105.e12
Open Access | Times Cited: 50
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Anna Kychygina, Myriam Cassagne, M. Tauber, et al.
Clinical Reviews in Allergy & Immunology (2022) Vol. 62, Iss. 3, pp. 519-533
Closed Access | Times Cited: 47
Medical treatment of eosinophilic esophagitis
Hannah F. Marshall, Melvin Lee Qiyu
Clinical & Experimental Allergy (2024) Vol. 54, Iss. 6, pp. 374-377
Closed Access | Times Cited: 9
Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis
Elizabeth Adesanya, Julian Matthewman, Yochai Schonmann, et al.
British Journal of Dermatology (2022) Vol. 188, Iss. 4, pp. 460-470
Open Access | Times Cited: 28
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate‐to‐severe atopic dermatitis
Jan Hartmann, Lucas Moitinho‐Silva, Nicole Sander, et al.
Allergy (2023) Vol. 78, Iss. 8, pp. 2290-2300
Open Access | Times Cited: 18
Systemtherapie der Neurodermitis und Psoriasis im Kindes- und Jugendalter
Michael Sticherling
Deleted Journal (2025)
Closed Access
EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis
Ioana Agache, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Allergy (2020) Vol. 76, Iss. 4, pp. 988-1009
Open Access | Times Cited: 37
COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
Marek Jutel, Marı́a José Torres, Óscar Palomares, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2313-2336
Open Access | Times Cited: 18
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
Edinson López, Raúl Cabrera, Cristóbal Lecaros
Anais Brasileiros de Dermatologia (2024) Vol. 99, Iss. 4, pp. 546-567
Open Access | Times Cited: 3
Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study
Serena Yun‐Chen Tsai, Jonathan M. Gaffin, Elena B. Hawryluk, et al.
Allergy (2024) Vol. 79, Iss. 10, pp. 2748-2758
Closed Access | Times Cited: 3
Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
Firas Constantin Kreeshan, Ali Al‐Janabi, Richard B. Warren, et al.
Dermatology and Therapy (2020) Vol. 11, Iss. 1, pp. 149-160
Open Access | Times Cited: 22
Safety of dupilumab in patients with atopic dermatitis: expert opinion
Wojciech Francuzik, Aikaterina Alexiou, Margitta Worm
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 9, pp. 997-1004
Closed Access | Times Cited: 20
Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis – a meta-analysis of randomized clinical trials
Monika Marko, Rafał Pawliczak
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 1, pp. 121-134
Closed Access | Times Cited: 7
Dupilumab therapy improves gut microbiome dysbiosis and tryptophan metabolism in Chinese patients with atopic dermatitis
Liu Yang, Danqi Li, Shuomin Sun, et al.
International Immunopharmacology (2024) Vol. 131, pp. 111867-111867
Closed Access | Times Cited: 2
An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis
Giorgio Ciprandi, Amelia Licari, Maria Angela Tosca, et al.
Pediatric Allergy and Immunology (2024) Vol. 35, Iss. 6
Closed Access | Times Cited: 2
Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
Bingjing Zhou, Cong Peng, Liqiao Li, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 12
Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance
Jefferson Russo Victor, Dong‐Ho Nahm
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
IL‐13 modulates ∆Np63 levels causing altered expression of barrier‐ and inflammation‐related molecules in human keratinocytes: A possible explanation for chronicity of atopic dermatitis
Terufumi Kubo, Sayuri Sato, Tokimasa Hida, et al.
Immunity Inflammation and Disease (2021) Vol. 9, Iss. 3, pp. 734-745
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top